B cells expressing IFN-γ suppress Treg-cell differentiation and promote autoimmune experimental arthritis

European Journal of Immunology

Volumn 45, Issue 4, 2015, Pages 988-998

  Olalekan, Susan A ^a   Cao, Yanxia ^a   Hamel, Keith M ^b   Finnegan, Alison ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Arthritis; Autoimmunity; B cells; IFN ; Treg cells

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; L SELECTIN; THY 1 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; AGGRECAN; CYTOKINE; DIMETHYLDIOCTADECYLAMMONIUM; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; QUATERNARY AMMONIUM DERIVATIVE; RITUXIMAB;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; EXPERIMENTAL ARTHRITIS; FEMALE; HUMORAL IMMUNE DEFICIENCY; IN VIVO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; RHEUMATOID ARTHRITIS;

ADJUVANTS, IMMUNOLOGIC; AGGRECANS; ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; QUATERNARY AMMONIUM COMPOUNDS; RITUXIMAB; T-LYMPHOCYTES, REGULATORY;

EID: 84926635001     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201445036     Document Type: Article

References (55)

1. Goronzy, J. J. and Weyand, C. M., Rheumatoid arthritis. In Klippell, J. H. (Ed.), Primer on rheumatic diseases, 11 Edn, Arthritis Foundation, Atlanta, 1997, pp. 155-173.
2. Edwards, J. C. and Cambridge, G., Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001. 40: 205-211.
3. Edwards, J. C., Szczepanski, L., Szechinski, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M. et al., Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 2004. 350: 2572-2581.
4. Pescovitz, M. D., Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am. J. Transplant. 2006. 6: 859-866.
5. Hamel, K., Doodes, P., Cao, Y., Wang, Y., Martinson, J., Dunn, R., Kehry, M. R. et al., Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity. J. Immunol. 2008. 180: 4994-5003.
6. Sfikakis, P. P., Boletis, J. N. and Tsokos, G. C., Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr. Opin. Rheumatol. 2005. 17: 550-557.
7. Eming, R., Nagel, A., Wolff-Franke, S., Podstawa, E., Debus, D. and Hertl, M., Rituximab exerts a dual effect in pemphigus vulgaris. J. Invest. Dermatol. 2008. 128: 2850-2858.
8. Stasi, R., Del Poeta, G., Stipa, E., Evangelista, M. L., Trawinska, M. M., Cooper, N. and Amadori, S., Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007. 110: 2924-2930.
9. Yanaba, K., Hamaguchi, Y., Venturi, G. M., Steeber, D. A., St Clair, E. W. and Tedder, T. F., B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J. Immunol. 2007. 179: 1369-1380.
10. Hamel, K. M., Cao, Y., Ashaye, S., Wang, Y., Dunn, R., Kehry, M. R., Glant, T. T. et al., B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis. J. Immunol. 2011. 187: 4900-4906.
11. Rudensky, A. Y., Regulatory T cells and Foxp3. Immunol. Rev. 2011. 241: 260-268.
12. Leipe, J., Skapenko, A., Lipsky, P. E. and Schulze-Koops, H., Regulatory T cells in rheumatoid arthritis. Arthritis Res. Ther. 2005. 7: 93-99.
13. Cao, D., vanVollenhoven, R., Klareskog, L., Trollmo, C. and Malmstrom, V., CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res. Ther. 2004. 6: R335-R346.
14. Ehrenstein, M. R., Evans, J. G., Singh, A., Moore, S., Warnes, G., Isenberg, D. A. and Mauri, C., Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 2004. 200: 277-285.
15. Valencia, X., Stephens, G., Goldbach-Mansky, R., Wilson, M., Shevach, E. M. and Lipsky, P. E., TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006. 108: 253-261.
16. Nadkarni, S., Mauri, C. and Ehrenstein, M. R., Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J. Exp. Med. 2007. 204: 33-39.
17. Dorner, T., Jacobi, A. M. and Lipsky, P. E., B cells in autoimmunity. Arthritis Res. Ther. 2009. 11: 247.
18. Lund, F. E. and Randall, T. D., Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat. Rev. Immunol. 2010. 10: 236-247.
19. Finnegan, A., Grusby, M. J., Kaplan, C. D., O'Neill, S. K., Eibel, H., Koreny, T., Czipri, M. et al., IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J. Immunol. 2002. 169: 3345-3352.
20. Wei, B., Baker, S., Wieckiewicz, J. and Wood, K. J., IFN-gamma triggered STAT1-PKB/AKT signalling pathway influences the function of alloantigen reactive regulatory T cells. Am. J. Transplant. 2010. 10: 69-80.
21. Feng, T., Cao, A. T., Weaver, C. T., Elson, C. O. and Cong, Y., Interleukin-12 converts Foxp3+ regulatory T cells to interferon-gamma-producing Foxp3+ T cells that inhibit colitis. Gastroenterology 2011. 140: 2031-2043.
22. Sawitzki, B., Kingsley, C. I., Oliveira, V., Karim, M., Herber, M. and Wood, K. J., IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J. Exp. Med. 2005. 201: 1925-1935.
23. Koenecke, C., Lee, C. W., Thamm, K., Fohse, L., Schafferus, M., Mittrucker, H. W., Floess, S. et al., IFN-gamma production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease. J. Immunol. 2012. 189: 2890-2896.
24. Bao, Y., Liu, X., Han, C., Xu, S., Xie, B., Zhang, Q., Gu, Y. et al., Identification of IFN-gamma-producing innate B cells. Cell Res. 2014. 24: 161-176.
25. Yeo, L., Toellner, K. M., Salmon, M., Filer, A., Buckley, C. D., Raza, K. and Scheel-Toellner, D., Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann. Rheum. Dis. 2011. 70: 2022-2028.
26. Chattopadhyay, G. and Shevach, E. M., Antigen-specific induced T regulatory cells impair dendritic cell function via an IL-10/MARCH1-dependent mechanism. J. Immunol. 2013. 191: 5875-5884.
27. Caretto, D., Katzman, S. D., Villarino, A. V., Gallo, E. and Abbas, A. K., Cutting edge: the Th1 response inhibits the generation of peripheral regulatory T cells. J. Immunol. 2010. 184: 30-34.
28. Doodes, P. D., Cao, Y., Hamel, K. M., Wang, Y., Rodeghero, R. L., Mikecz, K., Glant, T. T., Iwakura, Y. et al., IFN-gamma regulates the requirement for IL-17 in proteoglycan-induced arthritis. J. Immunol. 2010. 184: 1552-1559.
29. Goodman, W. A., Young, A. B., McCormick, T. S., Cooper, K. D. and Levine, A. D., Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J. Immunol. 2011. 186: 3336-3345.
30. Kretschmer, K., Apostolou, I., Hawiger, D., Khazaie, K., Nussenzweig, M. C. and vonBoehmer, H., Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 2005. 6: 1219-1227.
31. Knoechel, B., Lohr, J., Kahn, E., Bluestone, J. A. and Abbas, A. K., Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J. Exp. Med. 2005. 202: 1375-1386.
32. Harris, D. P., Goodrich, S., Gerth, A. J., Peng, S. L. and Lund, F. E., Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor. J. Immunol. 2005. 174: 6781-6790.
33. Dominguez-Villar, M., Baecher-Allan, C. M. and Hafler, D. A., Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat. Med. 2011. 17: 673-675.
34. Chang, J. H., Kim, Y. J., Han, S. H. and Kang, C. Y., IFN-gamma-STAT1 signal regulates the differentiation of inducible Treg: potential role for ROS-mediated apoptosis. Eur. J. Immunol. 2009. 39: 1241-1251.
35. Xin, L., Ertelt, J. M., Rowe, J. H., Jiang, T. T., Kinder, J. M., Chaturvedi, V., Elahi, S. et al., Cutting edge: committed Th1 CD4+ T cell differentiation blocks pregnancy-induced Foxp3 expression with antigen-specific fetal loss. J. Immunol. 2014. 192: 2970-2974.
36. Wang, Z., Hong, J., Sun, W., Xu, G., Li, N., Chen, X., Liu, A. et al., Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J. Clin. Invest. 2006. 116: 2434-2441.
37. Youinou, P., Taher, T. E., Pers, J. O., Mageed, R. A. and Renaudineau, Y., B lymphocyte cytokines and rheumatic autoimmune disease. Arthritis Rheum. 2009. 60: 1873-1880.
38. Lund, F. E., Cytokine-producing B lymphocytes-key regulators of immunity. Curr. Opin. Immunol. 2008. 20: 332-338.
39. Harris, D. P., Haynes, L., Sayles, P. C., Duso, D. K., Eaton, S. M., Lepak, N. M., Johnson, L. L. et al., Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat. Immunol. 2000. 1: 475-481.
40. Yanaba, K., Bouaziz, J. D., Haas, K. M., Poe, J. C., Fujimoto, M. and Tedder, T. F., A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 2008. 28: 639-650.
41. Bouaziz, J. D., Yanaba, K. and Tedder, T. F., Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 2008. 224: 201-214.
42. Darrasse-Jeze, G., Deroubaix, S., Mouquet, H., Victora, G. D., Eisenreich, T., Yao, K. H., Masilamani, R. F. et al., Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J. Exp. Med. 2009. 206: 1853-1862.
43. Murai, M., Turovskaya, O., Kim, G., Madan, R., Karp, C. L., Cheroutre, H. and Kronenberg, M., Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat. Immunol. 2009. 10: 1178-1184.
44. Sun, J. B., Flach, C. F., Czerkinsky, C. and Holmgren, J., B lymphocytes promote expansion of regulatory T cells in oral tolerance: powerful induction by antigen coupled to cholera toxin B subunit. J. Immunol. 2008. 181: 8278-8287.
45. Tadmor, T., Zhang, Y., Cho, H. M., Podack, E. R. and Rosenblatt, J. D., The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model. Cancer Immunol. Immunother. 2011. 60: 609-619.
46. Bermejo, D. A., Jackson, S. W., Gorosito-Serran, M., Acosta-Rodriguez, E. V., Amezcua-Vesely, M. C., Sather, B. D., Singh, A. K. et al., Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORgammat and Ahr that leads to IL-17 production by activated B cells. Nat. Immunol. 2013. 14: 514-522.
47. Rauch, P. J., Chudnovskiy, A., Robbins, C. S., Weber, G. F., Etzrodt, M., Hilgendorf, I., Tiglao, E. et al., Innate response activator B cells protect against microbial sepsis. Science 2012. 335: 597-601.
48. Shen, P., Roch, T., Lampropoulou, V., O'Connor, R. A., Stervbo, U., Hilgenberg, E., Ries, S. et al, IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 2014. 507: 366-370.
49. Barr, T. A., Shen, P., Brown, S., Lampropoulou, V., Roch, T., Lawrie, S., Fan, B. et al., B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J. Exp. Med. 2012. 209: 1001-1010.
50. Montandon, R., Korniotis, S., Layseca-Espinosa, E., Gras, C., Megret, J., Ezine, S., Dy, M. et al., Innate pro-B-cell progenitors protect against type 1 diabetes by regulating autoimmune effector T cells. Proc. Natl. Acad. Sci. USA 2013. 110: E2199-E2208.
51. Misumi, I. and Whitmire, J. K., B cell depletion curtails CD4+ T cell memory and reduces protection against disseminating virus infection. J. Immunol. 2014. 192: 1597-1608.
52. Whitmire, J. K., Asano, M. S., Kaech, S. M., Sarkar, S., Hannum, L. G., Shlomchik, M. J. and Ahmed, R., Requirement of B cells for generating CD4+ T cell memory. J. Immunol. 2009. 182: 1868-1876.
53. Sojka, D. K. and Fowell, D. J., Regulatory T cells inhibit acute IFN-gamma synthesis without blocking T-helper cell type 1 (Th1) differentiation via a compartmentalized requirement for IL-10. Proc. Natl. Acad. Sci. USA 2011. 108: 18336-18341.
54. Rodeghero, R., Cao, Y., Olalekan, S. A., Iwakua, Y., Glant, T. T. and Finnegan, A., Location of CD4+ T cell priming regulates the differentiation of Th1 and Th17 cells and their contribution to arthritis. J. Immunol. 2013. 190: 5423-5435.
55. Glant, T. T., Radacs, M., Nagyeri, G., Olasz, K., Laszlo, A., Boldizsar, F., Hegyi, A. et al., Proteoglycan (PG)-induced arthritis (PGIA) and recombinant human PG-G1 domain-induced arthritis (GIA) in BALB/c mice resembling two subtypes of rheumatoid arthritis. Arthritis Rheum. 2011. 63: 1312-1321.